Tisagenlecleucel Efficacious, Durable in Relapsed/Refractory Follicular Lymphoma
Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.
Exploring Advanced Approaches for Pain Relief
The chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
Valoctocogene Roxaparvovec’s Treatment Durability in Hemophilia A in Question
A drop in endogenous Factor VIII expression was observed from treatment to 5-year follow-up despite continued demonstration of efficacy.
Novel Therapies in Development for Dravet Syndrome
Joseph Sullivan, MD, and Elaine C. Wirrell, MD, discuss new developments for the treatment of Dravet syndrome beyond seizure control including gene editing and therapy.
Improving Efficiency in CAR T Cell Therapy Production
The chief technology officer of Mustang Bio discussed the company’s approach and future plans in CAR T production.
HER2-Specific CAR T Therapy Shows Safety and Efficacy in Pediatric Tumors
Encouraging results from the phase 1 BrainChild-01 trial were recently published.
ctDNA Changes May Predict CD19-Targeted CAR T-cell Therapy Response in LBCL
Heterogeneity in the cellular and molecular features of CAR T-cell products contributes to variation in efficacy and toxicity follow treatment with axicabtagene ciloleucel.
HuCART19 Efficacious and Durable in B-cell Acute Lymphoblastic Leukemia
huCART19 is designed to yield longer remission rates for pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Ide-Cel Shows Durable Response in R/R Multiple Myeloma: Larry D. Anderson, Jr, MD, PhD
The hematologist/oncologist from the Harold C. Simmons Comprehensive Cancer Center discussed the updated results of the KarMMa trial in relapsed/refractory multiple myeloma.
First Patient With Retinitis Pigmentosa Dosed in Trial of MCO-010
MCO-010 is designed to deliver multi-characteristic opsin to retinal cells.
CD20-Targeted Gene Therapy
Manuel Litchman, MD, the president, chief executive officer, and director of Mustang Bio discussed the company’s lead and second program.
Orca-T for Graft-Versus-Host Disease: Mehrdad Abedi, MD
The professor of medicine at the UC Davis Comprehensive Cancer Center discussed Orca-T, a high precision cell therapy, for patients with acute and chronic graft-vs-host disease.
OpRegen Shows Sustained Efficacy in Treating Dry AMD
Three patients continue to show improvements in BCVA 3 years post-treatment.
Challenges in Conducting Research in DMD
The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed some challenges the company is facing.
Novel Therapies in Heavily Pretreated Multiple Myeloma: Omar Nadeem, MD
The physician from the Dana-Farber Cancer Institute discussed the uptake of novel therapies in heavily pretreated multiple myeloma.
Celyad Announces Positive Data and Updates for CAR T Candidates
The phase 1b KEYNOTE-B79 trial of CYAD-101 for mCRC is expected to initiate in Q4 2021.
Investigating CAR T in Lymphoma, Leukemia, and Solid Tumors
The president, chief executive officer, and director of Mustang Bio discussed the company’s pipeline.
Future Research With Car T-Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed future research with CAR T-cell therapy in multiple myeloma.
Improving CAR Lymphoma Treatments With Epstein-Barr Virus T-Cell Therapy
Findings from an ongoing phase 1 trial were presented at the 2021 ASGCT meeting.
Making Antigen-Presenting Cells With Cell Squeeze Technology
The founder and chief executive officer of SQZ Biotech discussed the potential of their APC platform to treat a variety of tumors.
Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD
The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.
Valoctocogene Roxaparvovec Efficacious in Treating Hemophilia A
Over 90% participants had an annualized bleeding rate of 0 or a lower bleed rate than baseline after week 4 after treatment.
Integrating Ide-Cel Into Pretreated Multiple Myeloma Regimens: Shaji Kumar, MD
The hematologist from Mayo Clinic discussed the integration of CAR T-cell therapy into the treatment paradigm for heavily pretreated multiple myeloma.
Looking Forward in Relapsed/Refractory Multiple Myeloma Treatments
James Hoffman, MD, leads a discussion about recently approved therapies and exciting future treatment options for relapsed/refractory multiple myeloma.
Data Continues to Support the Use of NKT Cells in Pediatric Neuroblastoma
Early safety and efficacy data support the use of natural killer T (NKT) cells in patients with stage IV relapsed/refractory neuroblastoma.
Mitigating Adverse Events in CAR T-Cell Therapy: Mounzer Agha, MD
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.
Clinical Implications of Tisagenlecleucel in B-ALL Treatment: Michael R. Grunwald, MD, FACP
The hematologic oncologist at the Levine Cancer Institute discussed the clinical implications of tisagenlecleucel in the treatment of patients with B-cell acute lymphoblastic leukemia.
First Patient Dosed in Trial of GEN-011 for Treating Solid Tumors
The TiTAN-1 clinical trial is assessing the effect of GEN-011 on melanoma and various types of carcinomas.
The Potential of Gene Transfer Therapy in SMA
John Brandsema, MD, discusses gene transfer for the management of SMA and the recent approval of onasemnogene abeparvovec-xioi.
Prime Medicine Takes Precise Approach to Gene Editing With “Find and Replace” Technology
The precision gene editing technology is designed to minimize off-target genetic alterations.
